{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:46Z","timestamp":1793242306468,"version":"4.5.0"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>The effect of mogamulizumab in cutaneous T\u2010cell lymphoma (CTCL) on T\u00a0cells (TC) in the peripheral blood and its potential role to navigate treatment intervals are explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We investigated within a retrospective monocentric analysis the effect of mogamulizumab on the CD3<jats:sup>+<\/jats:sup> TC and the aberrant T\u00a0cell population (TCP), i.e., the CD4<jats:sup>+<\/jats:sup>\/CD7<jats:sup>\u2013<\/jats:sup> and the CD4<jats:sup>+<\/jats:sup>\/CD26<jats:sup>\u2013<\/jats:sup> TC, analyzed by flow cytometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirteen patients with CTCL were included. After four cycles there was a mean reduction of 57% in CD3<jats:sup>+<\/jats:sup> TC, 72% in the CD4<jats:sup>+<\/jats:sup>\/CD7<jats:sup>\u2013<\/jats:sup> and 75% in the CD4<jats:sup>+<\/jats:sup>\/CD26<jats:sup>\u2013<\/jats:sup> TCP compared to the individual baseline of each patient. The reduction in CD4<jats:sup>+<\/jats:sup>\/CD7<jats:sup>+<\/jats:sup> and CD4<jats:sup>+<\/jats:sup>\/CD26<jats:sup>+<\/jats:sup> TC was lower, averaging 54% and 41%. A significant decrease in aberrant TCP was already evident after the first administration. A median plateau of TCP already occurred during the IP. Progressive disease occurred in 5\/13 patients without a clear correlation to aberrant TCP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Already after one dose of mogamulizumab, aberrant TCP and, to a lesser extent, normal TC decrease. We did not observe a clear correlation between TCP and the efficacy of mogamulizumab, but further studies with larger numbers of patients are needed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.15144","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T06:33:41Z","timestamp":1688452421000},"page":"992-1002","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effect of mogamulizumab on the aberrant T\u00a0cell population in the peripheral blood \u2013 A monocentric retrospective analysis"],"prefix":"10.1111","volume":"21","author":[{"given":"Janika","family":"Gosmann","sequence":"first","affiliation":[{"name":"University Department for Dermatology Venereology Allergology and Phlebology Skin Cancer Center Johannes Wesling Medical Center Minden Ruhr University Bochum  Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bielefeld","sequence":"additional","affiliation":[{"name":"Institute for laboratory medicine microbiology environmental medicine and transfusion medicine Johannes Wesling Medical Center Minden Ruhr University Bochum  Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz\u2010Josef","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Institute for laboratory medicine microbiology environmental medicine and transfusion medicine Johannes Wesling Medical Center Minden Ruhr University Bochum  Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schaper\u2010Gerhardt","sequence":"additional","affiliation":[{"name":"University Department for Dermatology Venereology Allergology and Phlebology Skin Cancer Center Johannes Wesling Medical Center Minden Ruhr University Bochum  Minden Germany"},{"name":"Department of Dermatology Allergology and Venereology Hannover Skin Cancer Center (HTZH) Hannover Medical School  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[{"name":"University Department for Dermatology Venereology Allergology and Phlebology Skin Cancer Center Johannes Wesling Medical Center Minden Ruhr University Bochum  Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[{"name":"University Department for Dermatology Venereology Allergology and Phlebology Skin Cancer Center Johannes Wesling Medical Center Minden Ruhr University Bochum  Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"European Medicines Agency. Product information Poteligeo. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/poteligeo\u2010epar\u2010product\u2010information_de.pdf[Last accessed December 12 2022]."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(22)00548-2"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012057"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014468"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016594"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21888"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012286"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(02)00046-4"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01934.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17523"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18549"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1953007"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S377015"},{"issue":"3","key":"e_1_2_6_16_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/ddg.14657","article-title":"Low\u2010dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T\u2010cell lymphoma","volume":"20","author":"Elsayad K","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ddg.14725","article-title":"Care structure of patients with mycosis fungoides and S\u00e9zary syndrome in Germany \u2010 Care research based on SHI claims data","volume":"20","author":"Assaf C","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"9","key":"e_1_2_6_18_1","first-page":"1307","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"19","author":"Jonak C","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"issue":"9","key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/ddg.14571","article-title":"Psoriasis vulgaris triggered by treatment with mogamulizumab in a patient with cutaneous T\u2010cell lymphoma","volume":"19","author":"Lehner GM","year":"2021","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T04:02:16Z","timestamp":1703736136000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.15144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/ddg.15144"],"URL":"https:\/\/doi.org\/10.1111\/ddg.15144","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"2022-12-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}